Trial
NCT02984683
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sanofi
Collaborators
—
Condition
Triple Negative Breast Cancer
Intervention
SAR566658 (ACT14884)
Why stopped
Study discontinued considering the limited clinical benefit combined with a higher than expected rate of known non-serious ophthalmological event.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-09-08